JOURNAL OF CHILEAN CHEMICAL SOCIETY

Vol 69 No 4 (2024): Journal of The Chilean Chemical Society
Short Communications

DNA-BASED NANOPARTICLES: A PLATFORM TO PROVIDE HIGH EN-CAPSULATION, STABILITY AND PROLONGED RELEASE FOR DOXORUBICIN

PDF
  • Maria Gabriela Villamizar Sarmiento,
  • Estefanía Elgueta,
  • Andrew F.G. Quest,
  • Felipe A. Oyarzún-Ampuero,
  • Mauricio Báez,
  • Ignacio Moreno-Villoslada
Maria Gabriela Villamizar Sarmiento
Universidad de Chile
Estefanía Elgueta
Department of Sciences and Pharmaceutical Technology, University of Chile, Santiago de Chile 8380494, Chile
Andrew F.G. Quest
Laboratory of Cellular Communication, Program of Cell and Molecular Biology, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile
Felipe A. Oyarzún-Ampuero
Department of Sciences and Pharmaceutical Technology, University of Chile, Santiago de Chile 8380494, Chile
Mauricio Báez
Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile
Ignacio Moreno-Villoslada
Instituto de Ciencias Químicas, Facultad de Ciencias, Universidad Austral de Chile, Casilla 567, Valdivia 5110033, Chi-le
Published August 17, 2025
Keywords
  • Nanomedicine; cancer; deoxyribonucleic acid; doxorubicin; aromatic interactions
How to Cite
Villamizar Sarmiento, M. G., Elgueta, E., Quest, A. F., Oyarzún-Ampuero, F. A., Báez, M., & Moreno-Villoslada, I. (2025). DNA-BASED NANOPARTICLES: A PLATFORM TO PROVIDE HIGH EN-CAPSULATION, STABILITY AND PROLONGED RELEASE FOR DOXORUBICIN. Journal of the Chilean Chemical Society, 69(4), 6209-6214. Retrieved from https://www.jcchems.com/index.php/JCCHEMS/article/view/2849

Copyright (c) 2024 SChQ

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Abstract

Abstract: Background/Objectives: Doxorubicin (DOX) is a potent drug for cancer treatment but presents limitations for encapsulation and prolonged release. Nanoparticles (NPs) are an alternative to mitigate these issues; nevertheless synthetic methods are often complex and inefficient. This study focus in the development of DNA-based NPs, using DNA as unique excipient allowing ionic and aromatic interactions with DOX. Methods: The NPs formation consists in the mixture of DNA and DOX in water (aromatic and non-aromatic polyelectrolytes were used as positive and negative controls, respectively). UV-visible and fluorescence spectroscopy were used to corroborate the DOX/DNA interactions and to elucidate the mode of binding. Turbidimetry, dynamic light scattering, laser Doppler anemometry, nanoparticle tracking analyses, ultrafiltration, and scanning transmission electron microcopy were used to characterize the efficiency of the process and the morphology of DOX/DNA NPs. In vitro release, viability in non-cancerous cells and stability tests were conducted to assess the release profile and safety of the NPs. Results: DOX associates with DNA through ionic and aromatic interactions forming spherical NPs (115-220 nm, polidispersity 0.3-0.5, ~-27 mV, 8-13x1011 NPs/mL) with DOX association efficiency of 66-80% and loading in the range of 40-60%. DOX/DNA NPs exhibited prolonged release (55% in 12 days), stability at storage (at least 8 weeks) and does not provide toxicity in non-cancerous cells. Conclusions: We provide a simple strategy to entrap and release DOX in the form of NPs in DNA based platforms. This strategy could be used for other aromatic anticancer drug and selecting DNA sequences able to support anticancer activity.

 

 

2849.jpg

PDF

References

  1. Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2024. 74(3): p. 229-263.
  2. Nagai, H. and Y.H. Kim, Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis, 2017. 9(3): p. 448-451.
  3. ReFaey, K., et al., Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes, 2021. 5(3): p. 645-653.
  4. Rache, B., et al., Transition towards cancer mortality predominance over cardiovascular disease mortality in Brazil, 2000–2019: a population-based study. The Lancet Regional Health – Americas, 2024. 39.
  5. Xia, W. and M.W. King, Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy. 2025. 12(4): p. 430.
  6. Melguizo, C., et al., Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Des Devel Ther, 2015. 9: p. 6433-44.
  7. Sritharan, S. and N. Sivalingam, A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci, 2021. 278: p. 119527.
  8. Methaneethorn, J., et al., Population pharmacokinetics of doxorubicin: A systematic review. Asia-Pacific Journal of Clinical Oncology, 2023. 19(1): p. 9-26.
  9. Sinha, S.J., et al., Emerging Research and Future Directions on Doxorubicin: A Snapshot. Asian Pac J Cancer Prev, 2025. 26(1): p. 5-15.
  10. Yu, L.-R. and V.G. Desai, Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers, in Biomarkers in Toxicology, V.B. Patel, V.R. Preedy, and R. Rajendram, Editors. 2023, Springer International Publishing: Cham. p. 677-703.
  11. Lele, K.A., et al., Targeting cardiotoxicity: the potential of Annona squamosa L. in doxorubicin therapy. In Silico Pharmacology, 2025. 13(1): p. 47.
  12. Linders, A.N., et al., A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. npj Aging, 2024. 10(1): p. 9.
  13. Gautam, S., et al., Recent doxorubicin-conjugates in cancer drug delivery: Exploring conjugation strategies for enhanced efficacy and reduced toxicity. International Journal of Pharmaceutics, 2025. 675: p. 125556.
  14. Ghahremanloo, A., et al., Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer. Scientific Reports, 2025. 15(1): p. 9798.
  15. Bisht, A., et al., A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research, 2025. 15(1): p. 102-133.
  16. Dehghani, B., M. Mirzaei, and A. Lohrasbi-Nejad, Characterization of Thermoresponsive Poly(N-vinylcaprolactam) Polymer Containing Doxorubicin-Loaded Niosomes: Synthesis, Structural Properties, and Anticancer Efficacy. Journal of Pharmaceutical Innovation, 2025. 20(1): p. 7.
  17. Zang, C., et al., Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy. Journal of Translational Medicine, 2024. 22(1): p. 879.
  18. Zhao, H., et al., Doxorubicin prodrug-based nanomedicines for the treatment of cancer. Eur J Med Chem, 2023. 258: p. 115612.
  19. Rodríguez, F., et al., Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules, 2022. 12(6).
  20. Fatima, W., et al., Controlled release of doxorubicin from gelatin-based nanoparticles: theoretical and experimental approach. Materials Advances, 2024. 5(6): p. 2347-2358.
  21. Norouzi, M., et al., Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Scientific Reports, 2020. 10(1): p. 11292.
  22. Misiak, P., et al., Doxorubicin-loaded polymeric nanoparticles containing ketoester-based block and cholesterol moiety as specific vehicles to fight estrogen-dependent breast cancer. Cancer Nanotechnology, 2023. 14(1): p. 23.
  23. Villamizar-Sarmiento, M.G., et al., The key role of the drug self-aggregation ability to obtain optimal nanocarriers based on aromatic-aromatic drug-polymer interactions. European Journal of Pharmaceutics and Biopharmaceutics, 2021. 166: p. 19-29.
  24. Villamizar-Sarmiento, M.G., et al., A New Methodology to Create Polymeric Nanocarriers Containing Hydrophilic Low Molecular-Weight Drugs: A Green Strategy Providing a Very High Drug Loading. Molecular Pharmaceutics, 2019. 16(7): p. 2892-2901.
  25. Villamizar-Sarmiento, M.G., et al., Colloidal nanomedicines with prolonged release of chloroquine based on interactions with aromatic polymers after mixing two liquids: from in silico simulation of nanoparticle formation to efficient in-bench scale up. Journal of Molecular Liquids, 2024. 395: p. 123906.
  26. Hu, Q., et al., DNA Nanotechnology-Enabled Drug Delivery Systems. Chem Rev, 2019. 119(10): p. 6459-6506.
  27. Chen, T., et al., DNA Nanotechnology for Cancer Diagnosis and Therapy. Int J Mol Sci, 2018. 19(6).
  28. Kumar, V., et al., DNA Nanotechnology for Cancer Therapy. Theranostics, 2016. 6(5): p. 710-725.
  29. Zhang, Q., et al., DNA origami as an in vivo drug delivery vehicle for cancer therapy. ACS Nano, 2014. 8(7): p. 6633-43.
  30. Zhao, Y.-X., et al., DNA Origami Delivery System for Cancer Therapy with Tunable Release Properties. ACS Nano, 2012. 6(10): p. 8684-8691.
  31. Li, J., et al., Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications. Chemical Society Reviews, 2016. 45(5): p. 1410-1431.
  32. Hurst, S.J., A.K. Lytton-Jean, and C.A. Mirkin, Maximizing DNA loading on a range of gold nanoparticle sizes. Anal Chem, 2006. 78(24): p. 8313-8.
  33. Khuu, A., et al., Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma. 2024. 13(22): p. 1869.
  34. Xiong, H., R.N. Veedu, and S.D. Diermeier, Recent Advances in Oligonucleotide Therapeutics in Oncology. Int J Mol Sci, 2021. 22(7).
  35. Oprea, M. and M. Ionita, Antisense oligonucleotides-based approaches for the treatment of multiple myeloma. International Journal of Biological Macromolecules, 2025. 291: p. 139186.
  36. Zhang, J., et al., A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy. Int J Nanomedicine, 2023. 18: p. 7605-7635.
  37. Kalaimani, K., et al., Recent advancements in small interfering RNA based therapeutic approach on breast cancer. European Journal of Pharmacology, 2024. 981: p. 176877.
  38. Liu, C., et al., mRNA-based cancer therapeutics. Nature Reviews Cancer, 2023. 23(8): p. 526-543.
  39. Kong, B., et al., mRNA: A promising platform for cancer immunotherapy. Advanced Drug Delivery Reviews, 2023. 199: p. 114993.
  40. Afzal, A., et al., Current Trends in Messenger RNA Technology for Cancer Therapeutics. Biomater Res, 2025. 29: p. 0178.
  41. Menon, A., et al., miRNA: A Promising Therapeutic Target in Cancer. Int J Mol Sci, 2022. 23(19).
  42. Szczepanek, J., M. Skorupa, and A. Tretyn, MicroRNA as a Potential Therapeutic Molecule in Cancer. Cells, 2022. 11(6).
  43. Wang, Z., et al., miRNA interplay: Mechanisms and therapeutic interventions in cancer. MedComm – Oncology, 2024. 3(4): p. e93.
  44. Kashanian, S., et al., Multi-spectroscopic DNA interaction studies of sunset yellow food additive. Mol Biol Rep, 2012. 39(12): p. 10045-51.
  45. Sirajuddin, M., S. Ali, and A. Badshah, Drug–DNA interactions and their study by UV–Visible, fluorescence spectroscopies and cyclic voltametry. Journal of Photochemistry and Photobiology B: Biology, 2013. 124: p. 1-19.
  46. Villamizar-Sarmiento, M.G., et al., Ionic Nanocomplexes of Hyaluronic Acid and Polyarginine to Form Solid Materials: A Green Methodology to Obtain Sponges with Biomedical Potential. 2019. 9(7): p. 944.
  47. Inostroza-Riquelme, M., et al., Encapsulation of Gold Nanostructures and Oil-in-Water Nanocarriers in Microgels with Biomedical Potential. 2018. 23(5): p. 1208.
  48. Zhang, Y., et al., DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. Aaps j, 2010. 12(3): p. 263-71.
  49. Zárate, A.M., et al., A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo. 2021. 22(16): p. 8372.
  50. Guerrero, S., et al., Curcumin-loaded nanoemulsion: a new safe and effective formulation to prevent tumor reincidence and metastasis. Nanoscale, 2018. 10(47): p. 22612-22622.
  51. Yaghoubi, A. and A. Ramazani, Anticancer DOX delivery system based on CNTs: Functionalization, targeting and novel technologies. J Control Release, 2020. 327: p. 198-224.
  52. Zarzhitsky, S. and H. Rapaport, The interactions between doxorubicin and amphiphilic and acidic β-sheet peptides towards drug delivery hydrogels. Journal of Colloid and Interface Science, 2011. 360(2): p. 525-531.
  53. Jawad, B., et al., Molecular mechanism and binding free energy of doxorubicin intercalation in DNA. Physical Chemistry Chemical Physics, 2019. 21(7): p. 3877-3893.
  54. Byrn, S.R. and G.D. Dolch, Analysis of Binding of Daunorubicin and Doxorubicin to DNA Using Computerized Curve-Fitting Procedures. Journal of Pharmaceutical Sciences, 1978. 67(5): p. 688-693.
  55. Chen, Z., et al., Investigation on the interaction between anthracyclines and DNA in the presence of paclitaxel by resonance light scattering technique. Microchimica Acta, 2012. 177(1): p. 67-73.
  56. Inamdar, P.R. and A. Sheela, Spectroscopic investigations on partial intercalative binding behaviour of terpyridine based copper(II) complexes with DNA. Journal of Photochemistry and Photobiology B: Biology, 2016. 159: p. 133-141.
  57. Agudelo, D., et al., Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity. Journal of Photochemistry and Photobiology B: Biology, 2016. 158: p. 274-279.
  58. Jiang, S.-P., et al., Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. International Journal of Nanomedicine, 2013. 8: p. 3141-50.
  59. Alyane, M., G. Barratt, and M. Lahouel, Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. Saudi Pharm J, 2016. 24(2): p. 165-75.
  60. Assali, M., N. Jaradat, and L. Maqboul, The Formation of Self-Assembled Nanoparticles Loaded with Doxorubicin and d-Limonene for Cancer Therapy. ACS Omega, 2022. 7(46): p. 42096-42104.
  61. Ahmed, L., et al., Study the Using of Nanoparticles as Drug Delivery System Based on Mathematical Models for Controlled Release. 2019. 8: p. 52-56.
  62. Heredia, N.S., et al., Comparative statistical analysis of the release kinetics models for nanoprecipitated drug delivery systems based on poly(lactic-co-glycolic acid). PLoS One, 2022. 17(3): p. e0264825.
  63. Contri, R.V., et al., Drug Release from Pharmaceutical Nanocarriers, in The ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics, A. Talevi, Editor. 2022, Springer International Publishing: Cham. p. 419-428.
  64. Zhang, B., et al., The anti-tumor and renoprotection study of E-[c(RGDfK)2]/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride/salvianolic acid A. Journal of Nanobiotechnology, 2022. 20(1): p. 425.

Copyright @2019 | Designed by: Open Journal Systems Chile Logo Open Journal Systems Chile Support OJS, training, DOI, Indexing, Hosting OJS

Code under GNU license: OJS PKP